JP2017536382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536382A5 JP2017536382A5 JP2017528775A JP2017528775A JP2017536382A5 JP 2017536382 A5 JP2017536382 A5 JP 2017536382A5 JP 2017528775 A JP2017528775 A JP 2017528775A JP 2017528775 A JP2017528775 A JP 2017528775A JP 2017536382 A5 JP2017536382 A5 JP 2017536382A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- salt
- species
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 27
- -1 4- (4- (4-(((3R Chemical class 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 206010017533 Fungal infection Diseases 0.000 claims description 12
- 208000024386 fungal infectious disease Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 241000228212 Aspergillus Species 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 6
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004413 flucytosine Drugs 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical group CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 claims description 2
- ZMYFCFLJBGAQRS-IRXDYDNUSA-N (2R,3S)-epoxiconazole Chemical compound C1=CC(F)=CC=C1[C@@]1(CN2N=CN=C2)[C@H](C=2C(=CC=CC=2)Cl)O1 ZMYFCFLJBGAQRS-IRXDYDNUSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims description 2
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 2
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 2
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 claims description 2
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 claims description 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 241000222122 Candida albicans Species 0.000 claims description 2
- 108010020326 Caspofungin Proteins 0.000 claims description 2
- 201000007336 Cryptococcosis Diseases 0.000 claims description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 2
- 108010049047 Echinocandins Proteins 0.000 claims description 2
- 239000005767 Epoxiconazole Substances 0.000 claims description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 2
- 229930195098 Hamycin Natural products 0.000 claims description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 2
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 2
- 241000228143 Penicillium Species 0.000 claims description 2
- 241000228150 Penicillium chrysogenum Species 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005822 Propiconazole Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- 241000235527 Rhizopus Species 0.000 claims description 2
- 240000005384 Rhizopus oryzae Species 0.000 claims description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims description 2
- AWGBZRVEGDNLDZ-UHFFFAOYSA-N Rimocidin Natural products C1C(C(C(O)C2)C(O)=O)OC2(O)CC(O)CCCC(=O)CC(O)C(CC)C(=O)OC(CCC)CC=CC=CC=CC=CC1OC1OC(C)C(O)C(N)C1O AWGBZRVEGDNLDZ-UHFFFAOYSA-N 0.000 claims description 2
- AWGBZRVEGDNLDZ-JCUCCFEFSA-N Rimocidine Chemical compound O([C@H]1/C=C/C=C/C=C/C=C/C[C@H](OC(=O)[C@@H](CC)[C@H](O)CC(=O)CCC[C@H](O)C[C@@]2(O)O[C@H]([C@@H]([C@@H](O)C2)C(O)=O)C1)CCC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O AWGBZRVEGDNLDZ-JCUCCFEFSA-N 0.000 claims description 2
- 241000223238 Trichophyton Species 0.000 claims description 2
- 241000222126 [Candida] glabrata Species 0.000 claims description 2
- TYBHXIFFPVFXQW-UHFFFAOYSA-N abafungin Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CSC(NC=2NCCCN=2)=N1 TYBHXIFFPVFXQW-UHFFFAOYSA-N 0.000 claims description 2
- 229950006373 abafungin Drugs 0.000 claims description 2
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 claims description 2
- 229950006816 albaconazole Drugs 0.000 claims description 2
- 229960003204 amorolfine Drugs 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960002206 bifonazole Drugs 0.000 claims description 2
- 229960002962 butenafine Drugs 0.000 claims description 2
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004348 candicidin Drugs 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 208000032343 candida glabrata infection Diseases 0.000 claims description 2
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 2
- 229960003034 caspofungin Drugs 0.000 claims description 2
- 229960003749 ciclopirox Drugs 0.000 claims description 2
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 229960003937 efinaconazole Drugs 0.000 claims description 2
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 claims description 2
- 229960001274 fenticonazole Drugs 0.000 claims description 2
- 229960004884 fluconazole Drugs 0.000 claims description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003765 fluvastatin Drugs 0.000 claims description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 2
- 229960002867 griseofulvin Drugs 0.000 claims description 2
- 229950006942 hamycin Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004849 isoconazole Drugs 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 229960000570 luliconazole Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229960003255 natamycin Drugs 0.000 claims description 2
- 235000010298 natamycin Nutrition 0.000 claims description 2
- 239000004311 natamycin Substances 0.000 claims description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 2
- 229960000988 nystatin Drugs 0.000 claims description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 2
- 229960004031 omoconazole Drugs 0.000 claims description 2
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 claims description 2
- 229960003483 oxiconazole Drugs 0.000 claims description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 229960001589 posaconazole Drugs 0.000 claims description 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- 229960005429 sertaconazole Drugs 0.000 claims description 2
- 229960002607 sulconazole Drugs 0.000 claims description 2
- 229960002722 terbinafine Drugs 0.000 claims description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 2
- 229960000580 terconazole Drugs 0.000 claims description 2
- 229960004880 tolnaftate Drugs 0.000 claims description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002703 undecylenic acid Drugs 0.000 claims description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 2
- 229960004740 voriconazole Drugs 0.000 claims description 2
- 241000130764 Tinea Species 0.000 claims 1
- 208000002474 Tinea Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 3
- 0 *C[C@@](C1)CO[C@@]1(C[n]1ncnc1)C1C(F)=CC(F)=CC1 Chemical compound *C[C@@](C1)CO[C@@]1(C[n]1ncnc1)C1C(F)=CC(F)=CC1 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196662.2 | 2014-12-05 | ||
| EP14196662 | 2014-12-05 | ||
| PCT/GB2015/053731 WO2016087878A1 (en) | 2014-12-05 | 2015-12-04 | Antimycotic compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536382A JP2017536382A (ja) | 2017-12-07 |
| JP2017536382A5 true JP2017536382A5 (enExample) | 2019-01-17 |
| JP6669751B2 JP6669751B2 (ja) | 2020-03-18 |
Family
ID=52006914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528775A Active JP6669751B2 (ja) | 2014-12-05 | 2015-12-04 | 抗真菌化合物 |
| JP2017528789A Active JP6666345B2 (ja) | 2014-12-05 | 2015-12-04 | 抗真菌化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528789A Active JP6666345B2 (ja) | 2014-12-05 | 2015-12-04 | 抗真菌化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (12) | US10106531B2 (enExample) |
| EP (2) | EP3227278B1 (enExample) |
| JP (2) | JP6669751B2 (enExample) |
| KR (1) | KR102579848B1 (enExample) |
| CN (2) | CN107001343B (enExample) |
| AU (1) | AU2015356795B2 (enExample) |
| BR (1) | BR112017008481B1 (enExample) |
| CA (1) | CA2963625C (enExample) |
| DK (2) | DK3227277T3 (enExample) |
| EA (1) | EA033736B1 (enExample) |
| ES (2) | ES2786374T3 (enExample) |
| HU (2) | HUE048685T2 (enExample) |
| IL (1) | IL251631B (enExample) |
| MX (1) | MX370412B (enExample) |
| PL (1) | PL3227277T3 (enExample) |
| PT (1) | PT3227277T (enExample) |
| SG (1) | SG11201702835RA (enExample) |
| WO (2) | WO2016087878A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3227277T3 (da) | 2014-12-05 | 2020-04-27 | Pulmocide Ltd | Antimykotisk forbindelse |
| WO2016097761A1 (en) | 2014-12-18 | 2016-06-23 | Pulmocide Limited | 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections |
| NZ735783A (en) | 2015-05-21 | 2021-12-24 | Pulmocide Ltd | Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof. |
| WO2017093491A1 (en) * | 2015-12-04 | 2017-06-08 | Pulmocide Limited | Antimycotic triazole compound |
| NZ754205A (en) * | 2016-11-28 | 2022-07-29 | Cellix Bio Private Ltd | Compositions and methods for the treatment of oral infectious diseases |
| WO2018115319A2 (en) | 2016-12-23 | 2018-06-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases |
| GB201917867D0 (en) | 2019-12-06 | 2020-01-22 | Pulmocide Ltd | Polymorphs |
| EP3858357A1 (en) * | 2020-01-28 | 2021-08-04 | Diaccurate | Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib |
| RU2770598C1 (ru) * | 2021-06-29 | 2022-04-18 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | ПРИМЕНЕНИЕ ПРОТИВОГРИБКОВОГО СРЕДСТВА НА ОСНОВЕ 2-((4-R1-5-R2-3-(ЭТОКСИКАРБОНИЛ)ТИОФЕН-2-ИЛ)АМИНО)-4-ОКСО-4-R3-БУТ-2-ЕНОВЫХ КИСЛОТ ПО ОТНОШЕНИЮ К Candida aldicans |
| WO2025114603A1 (en) | 2023-11-30 | 2025-06-05 | Basilea Pharmaceutica International Ag, Allschwil | Pharmaceutical combinations for use in the treatment of fungal infections |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5533466A (en) * | 1978-07-14 | 1980-03-08 | Janssen Pharmaceutica Nv | Novel azole derivatives and their manufacture |
| CH655103A5 (de) * | 1983-03-11 | 1986-03-27 | Sandoz Ag | Azolderivate, verfahren zu ihrer herstellung und ihre verwendung. |
| CA1292472C (en) | 1985-12-03 | 1991-11-26 | Alfonsus Guilielmus Knaeps | Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles |
| DE3609598A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| DE3852477T2 (de) | 1987-11-20 | 1995-05-04 | Schering Corp | Tri- und tetrasubstituierte Oxetane und Tetrahydrofurane und deren Zwischenprodukte. |
| US5039678A (en) | 1989-03-23 | 1991-08-13 | Wake Forest University | Method of increasing cranial vessel proliferation by administering nimodipine |
| US5039676A (en) | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
| US5403937A (en) * | 1993-04-30 | 1995-04-04 | Schering Corporation | Process for preparing intermediates for the synthesis of antifungal agents |
| US5714490A (en) | 1993-12-21 | 1998-02-03 | Schering Corporation | Tetrahydrofuran antifungals |
| SK283035B6 (sk) | 1993-12-21 | 2003-02-04 | Schering Corporation | Tetrahydrofuránová zlúčenina, spôsob jej prípravy, jej farmaceuticky prijateľný ester, soľ a farmaceutický prostriedok |
| US5486625A (en) | 1994-07-08 | 1996-01-23 | Schering Corporation | Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents |
| PL319635A1 (en) | 1995-06-02 | 1997-08-18 | Schering Corp | Tetrahydrofurane-based antimycotic agents |
| EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| AU2002257104B2 (en) | 2001-04-03 | 2006-02-09 | Merck Sharp & Dohme Corp. | Antifungal composition with enhanced bioavailability |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| EP2734517B1 (en) * | 2011-07-18 | 2017-08-30 | Merck Patent GmbH | Benzamides |
| WO2013036866A1 (en) | 2011-09-07 | 2013-03-14 | The Johns Hopkins University | Itraconazole analogs and use thereof |
| DK3227277T3 (da) * | 2014-12-05 | 2020-04-27 | Pulmocide Ltd | Antimykotisk forbindelse |
| GB201917867D0 (en) | 2019-12-06 | 2020-01-22 | Pulmocide Ltd | Polymorphs |
-
2015
- 2015-12-04 DK DK15808770.0T patent/DK3227277T3/da active
- 2015-12-04 PT PT158087700T patent/PT3227277T/pt unknown
- 2015-12-04 JP JP2017528775A patent/JP6669751B2/ja active Active
- 2015-12-04 SG SG11201702835RA patent/SG11201702835RA/en unknown
- 2015-12-04 AU AU2015356795A patent/AU2015356795B2/en active Active
- 2015-12-04 US US15/524,505 patent/US10106531B2/en active Active
- 2015-12-04 CA CA2963625A patent/CA2963625C/en active Active
- 2015-12-04 MX MX2017007188A patent/MX370412B/es active IP Right Grant
- 2015-12-04 ES ES15817507T patent/ES2786374T3/es active Active
- 2015-12-04 DK DK15817507.5T patent/DK3227278T3/da active
- 2015-12-04 ES ES15808770T patent/ES2790875T3/es active Active
- 2015-12-04 BR BR112017008481-3A patent/BR112017008481B1/pt active IP Right Grant
- 2015-12-04 JP JP2017528789A patent/JP6666345B2/ja active Active
- 2015-12-04 EA EA201791174A patent/EA033736B1/ru not_active IP Right Cessation
- 2015-12-04 EP EP15817507.5A patent/EP3227278B1/en active Active
- 2015-12-04 KR KR1020177013730A patent/KR102579848B1/ko active Active
- 2015-12-04 HU HUE15817507A patent/HUE048685T2/hu unknown
- 2015-12-04 CN CN201580066092.6A patent/CN107001343B/zh active Active
- 2015-12-04 PL PL15808770T patent/PL3227277T3/pl unknown
- 2015-12-04 HU HUE15808770A patent/HUE048905T2/hu unknown
- 2015-12-04 WO PCT/GB2015/053731 patent/WO2016087878A1/en not_active Ceased
- 2015-12-04 EP EP15808770.0A patent/EP3227277B1/en active Active
- 2015-12-04 WO PCT/GB2015/053733 patent/WO2016087880A1/en not_active Ceased
- 2015-12-04 CN CN202011308132.2A patent/CN112375073B/zh active Active
-
2016
- 2016-10-20 US US15/298,431 patent/US10093659B2/en active Active
-
2017
- 2017-04-06 IL IL251631A patent/IL251631B/en active IP Right Grant
-
2018
- 2018-09-12 US US16/129,322 patent/US10487073B2/en active Active
- 2018-09-24 US US16/139,591 patent/US10344022B2/en active Active
-
2019
- 2019-05-24 US US16/422,062 patent/US10450304B2/en active Active
- 2019-09-12 US US16/569,128 patent/US10662179B2/en active Active
- 2019-10-04 US US16/593,444 patent/US10800762B2/en active Active
-
2020
- 2020-04-15 US US16/849,476 patent/US10858345B2/en active Active
- 2020-09-04 US US17/012,685 patent/US11008307B2/en active Active
- 2020-11-04 US US17/089,441 patent/US11661415B2/en active Active
-
2021
- 2021-04-14 US US17/230,009 patent/US20210238169A1/en not_active Abandoned
-
2023
- 2023-04-18 US US18/302,557 patent/US12269814B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536382A5 (enExample) | ||
| JP2017536385A5 (enExample) | ||
| JP2017536371A5 (enExample) | ||
| JP2011500779A5 (enExample) | ||
| JP2017519036A5 (enExample) | ||
| CN107001343B (zh) | 抗真菌的化合物 | |
| US6407129B1 (en) | Azole compounds, their production and their use | |
| JP2006505576A (ja) | アリールアミジン誘導体を含む抗真菌薬 | |
| JP2011508774A5 (enExample) | ||
| AU2006339842A1 (en) | Pharmaceutical composition for external use | |
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| FI4069690T3 (fi) | Triatsolisienilääkeyhdiste pc945:n polymorfeja | |
| TW202412801A (zh) | 匹莫苯坦（ｐｉｍｏｂｅｎｄａｎ）用於在患有由二尖瓣疾病所致之無症狀心臟衰竭之患者中減小心臟大小及/或延遲臨床症狀之發作的用途 | |
| NZ613167A (en) | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds | |
| JP2013545819A5 (enExample) | ||
| JP2007534764A5 (enExample) | ||
| JP2019501879A5 (enExample) | ||
| FI120079B (fi) | Antifungaalisia koostumuksia, jotka sisältävät terbinafiinia ja atsoli-14(alfa)-metyylidemetyylaasi-estäjää | |
| JP2021503001A5 (enExample) | ||
| WO2005000287A1 (ja) | 水虫治療用外用剤 | |
| RU2006141653A (ru) | Доставка противогрибковых лекарственных средств | |
| US20210260196A1 (en) | Formulation comprising active pharmaceutical ingredient | |
| RU2009117207A (ru) | Фармацевтическая композиция, включающая производное фениламидина, и способ применения фармацевтической композиции в комбинации с противогрибковым средством | |
| CN105745193B (zh) | 抗真菌氧代二氢吡啶碳酰肼衍生物 | |
| JP2018520104A5 (enExample) |